Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David O Bates

Showing results (141-150 of 156) with videos related to

Pageof 16
Sort By:
Cancer Research|November 3, 2004
VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expressionJeanette Woolard, Wen-Ying Wang, Heather S Bevan, et al.
The Journal of Pathology|August 23, 2024
Single-cell transcriptomics identifies aberrant glomerular angiogenic signalling in the early stages of WT1 kidney diseaseJennifer C Chandler, Daniyal J Jafree, Saif Malik, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 24, 2009
Critical role of tissue kallikrein in vessel formation and maturation: implications for therapeutic revascularizationOliver A Stone, Christine Richer, Costanza Emanueli, et al.
Microcirculation (New York, N.Y. : 1994)|June 25, 2026
ZEB1 Modifies VE-Cadherin Signaling in Lymphatic Endothelial CellsNada S Ahmed, Joseph L Horder, Charles T Cresswell, et al.
Pharmaceuticals (Basel, Switzerland)|February 24, 2024
Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and MutationKyaw Zwar Myint, Brinda Balasubramanian, Simran Venkatraman, et al.
Molecular Oncology|September 17, 2014
Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistanceMaryam A Hamdollah Zadeh, Elianna M Amin, Coralie Hoareau-Aveilla, et al.
Cancer Cell|December 17, 2011
WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicingElianna M Amin, Sebastian Oltean, Jing Hua, et al.
Cardiovascular Diabetology|February 2, 2024
Heparanase inhibition as a systemic approach to protect the endothelial glycocalyx and prevent microvascular complications in diabetesMonica Gamez, Hesham E Elhegni, Sarah Fawaz, et al.
Cardiovascular Diabetology|February 20, 2024
Correction: Heparanase inhibition as a systemic approach to protect the endothelial glycocalyx and prevent microvascular complications in diabetesMonica Gamez, Hesham E Elhegni, Sarah Fawaz, et al.
American Journal of Physiology. Heart and Circulatory Physiology|June 30, 2025
The splicing factor kinase SRPK1 is a therapeutic target for peripheral vascular diseaseSohni Ria Bhalla, Mussarat Wahid, Jason O Amartey, et al.
Pageof 16

Showing results (141-150 of 156) with videos related to

Sort By:
Pageof 16
Cancer Research|November 3, 2004
VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expressionJeanette Woolard, Wen-Ying Wang, Heather S Bevan, et al.
The Journal of Pathology|August 23, 2024
Single-cell transcriptomics identifies aberrant glomerular angiogenic signalling in the early stages of WT1 kidney diseaseJennifer C Chandler, Daniyal J Jafree, Saif Malik, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 24, 2009
Critical role of tissue kallikrein in vessel formation and maturation: implications for therapeutic revascularizationOliver A Stone, Christine Richer, Costanza Emanueli, et al.
Microcirculation (New York, N.Y. : 1994)|June 25, 2026
ZEB1 Modifies VE-Cadherin Signaling in Lymphatic Endothelial CellsNada S Ahmed, Joseph L Horder, Charles T Cresswell, et al.
Pharmaceuticals (Basel, Switzerland)|February 24, 2024
Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and MutationKyaw Zwar Myint, Brinda Balasubramanian, Simran Venkatraman, et al.
Molecular Oncology|September 17, 2014
Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistanceMaryam A Hamdollah Zadeh, Elianna M Amin, Coralie Hoareau-Aveilla, et al.
Cancer Cell|December 17, 2011
WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicingElianna M Amin, Sebastian Oltean, Jing Hua, et al.
Cardiovascular Diabetology|February 2, 2024
Heparanase inhibition as a systemic approach to protect the endothelial glycocalyx and prevent microvascular complications in diabetesMonica Gamez, Hesham E Elhegni, Sarah Fawaz, et al.
Cardiovascular Diabetology|February 20, 2024
Correction: Heparanase inhibition as a systemic approach to protect the endothelial glycocalyx and prevent microvascular complications in diabetesMonica Gamez, Hesham E Elhegni, Sarah Fawaz, et al.
American Journal of Physiology. Heart and Circulatory Physiology|June 30, 2025
The splicing factor kinase SRPK1 is a therapeutic target for peripheral vascular diseaseSohni Ria Bhalla, Mussarat Wahid, Jason O Amartey, et al.
Pageof 16